The clinical candidate quisinostat was originally developed for the treatment of cancer (Figure ). This piperidinyl-pyrimidine-based hydroxamic acid is a pan-HDAC inhibitor with potent subnanomolar to submicromolar inhibitory activities against HDAC1-11. Quisinostat has been evaluated in multiple clinical studies for cutaneous T-cell lymphoma (CTCL, NCT01486277), ovarian cancer (NCT02948075), refractory leukemia (NCT00676728), and multiple myeoloma (NCT01464112). Recent research showed that quisinostat and its derivatives possess high antiplasmodial potential in vitro and in vivo. Although, the toxicity of quisinostat derivatives could be reduced through modifications in the linker and cap groups, most available analogs still exhibit substantial cytotoxic activity.